Skip to main content
Cellid Co., Ltd. logo

Cellid Co., Ltd. — Investor Relations & Filings

Ticker · 299660 ISIN · KR7299660001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2021-06-15 Major Shareholding Noti…
Country KR South Korea
Listing KO 299660

About Cellid Co., Ltd.

http://www.cellid.co.kr

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details a change in share ownership (specifically a decrease in stake by Amicogen in Cellid) and is filed with the Financial Supervisory Service/Korea Exchange. This falls under the category of 'Major Shareholding Notification' (MRQ) as it tracks significant ownership thresholds.
2021-06-15 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the granting of stock options (주식매수선택권 부여에 관한 신고). This type of disclosure is a standard regulatory requirement for public companies in Korea to report changes in capital structure or equity-based compensation plans. Since it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes), and it is a specific regulatory disclosure, it falls under the 'Regulatory Filings' category.
2021-06-11 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/Korea Exchange). It details the share transactions (specifically a sale of 20,000 shares) by an executive (Oh Tae-kwon) of Cellid Co., Ltd. This type of filing is a standard regulatory disclosure for insider trading/director dealings.
2021-06-11 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the change in share ownership by Amicogen (the reporter) in Cellid (the issuer). This falls under the category of Major Shareholding Notification (MRQ) as it tracks changes in significant share ownership levels.
2021-06-04 Korean
[기재정정]사업보고서 (2020.12)
Annual Report Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Business Report' (사업보고서), which is the Korean equivalent of a 10-K. The document contains detailed financial and operational updates, including dividend policies, capital changes, and management information, which are substantive components of an annual report. Since it is a formal correction to an existing annual report filing, it is classified as a 10-K. FY 2020
2021-06-02 Korean
기타경영사항(특허권취득)(자율공시)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent by the company Cellid. It details the patent name, content, and utilization plan. Since it is a regulatory announcement regarding a specific corporate event (patent acquisition) that does not fall into the specific categories of financial reports, dividends, or management changes, it is classified as a general regulatory filing.
2021-05-31 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.